Introduction
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), which historically has been considered an autoimmune inflammatory disorder. To date, the etiology of MS remains unknown; however, it likely results from a breakdown of immune tolerance related to genetic predisposition, environmental triggers, and immune dysregulation. The pathogenesis of MS appears to involve both inflammatory and neurodegenerative phases; however, the temporal and causal relationships between these entities remains unclear, specifically whether they occur either in tandem, parallel or both. The concept of an inflammatory phase is supported by studies of plaque formation, evidence of clinical relapses and MRI activity. The neurodegenerative period tends to involve slowing of clinical relapses, progressive accumulation of disability and loss of activity on MRI with development of cerebral atrophy. Pathologic studies support the presence of both inflammation and neurodegeneration, even in acute plaques, which contain activated macrophages and T cells as well as B cells, demyelinated axons and axonal injury [1] . Transition from the inflammatory to progressive phase may result from immune dysregulation secondary to inflammatory activity or even potentially subsequent to a loss of certain inflammatory mechanisms.
Our broad understanding of the immunopathogenesis of MS continues to foster translation into clinical research. Recent research has shed new insight into this complex pathophysiology, including the role of specific immune cells and cytokines as well as insight into remyelination and repair. As such, several new treatment trials examining promising therapies are under development and emerging therapeutic targets continue to be identified. In the meantime, in addition to new treatments, optimizing our current armamentarium of disease modifying therapies (DMTs) may also make an impact on the disease. Patients are being diagnosed and beginning treatment earlier and combination regimens are being studied in an effort to enhance existing therapies.
Building on existing therapies
After more than a decade, the introduction of DMTs has clearly made a significant impact on the treatment of patients with MS. Multiple clinical trials support the efficacy and tolerability of DMT. At present, six available DMT agents are US Food and Drug Administration (FDA) approved for use in relapsing-remitting MS (RRMS). These include: three interferon (IFN)-b preparations, glatiramer acetate, the monoclonal antibody natalizumab, and the chemotherapeutic agent mitoxantrone (MTX). Whereas there is clear and convincing evidence demonstrating their alteration of disease activity, as measured by both clinical and MRI parameters, the DMTs are nonetheless partially effective, and their longterm impact on disease progression remains unclear. Furthermore, their injectable route of administration and side effects can impede patient tolerability and adherence. As such, alternative more efficacious and well tolerated therapies are needed.
All injectable DMTs have demonstrated a beneficial effect on decreasing annual relapse rates, on average by approximately 30%, when compared with placebo. Whereas their efficacy appears similar, the caveat of comparisons across clinical trials limits our ability to ascertain therapeutic superiority. The interferons and glatiramer acetate have very distinct mechanisms of action. Interferons modulate antigen presentation via the downregulation of costimulatory molecules. While they do not exert direct effects in the CNS, their action in the periphery limits T-lymphocyte trafficking into the CNS by effects on matrix metalloproteinases and adhesion molecules. Furthermore, they reduce permeability of the blood-brain barrier (BBB). Glatiramer acetate's mechanism of action involves the production of glatiramer acetate-reactive T helper (Th)2 cells that cross the BBB and exert direct effects on the CNS inflammatory milieu, specifically increasing the secretion of suppressor-type cytokines and downregulating inflammatory activity.
Several studies have aimed at building upon the current DMTs to optimize therapeutic regimens. For example, initiating DMTs earlier appears to have a significant benefit on patient outcomes. Moreover, recent head-tohead data have suggested that the efficacy of interferons and glatiramer acetate may be similar, enabling clinicians to tailor treatments to individual patient preferences in terms of side effects and dose regimens in an effort to enhance tolerability and adherence. Furthermore, investigations of alternate dosing as well as combination therapies may also help enhance efficacy.
Early initiation of disease modifying therapy
To date, several studies, both in vitro and in vivo, have accumulated evidence supporting early initiation of DMT. Pathologic studies have demonstrated evidence of axonal injury occurring in acute MS plaques [2] and inflammatory axonal damage may occur even in the earliest stages of the disease [3] . The extension studies of the pivotal glatiramer acetate trial and Prevention of Relapses and Disability by Interferon-1a Subcutaneously in Multiple Sclerosis (PRISMS) trials both demonstrate that a 2-year delay in treatment can make a critically significant impact on development of disease progression [4] [5] [6] . Likewise, examining populations of patients with clinically isolated syndromes (CIS) and abnormal MRI suggestive of early MS has helped define the effect of early therapy on risk of conversion to clinically definite MS (CDMS). For example, results of the Early Treatment of MS Study (ETOMS), Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS), and, most recently, the Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) trials clearly demonstrate that early initiation of DMT is effective in delaying conversion to CDMS [7] [8] [9] [10] .
In the BENEFIT trial, 487 patients with CIS and at least two white matter lesions on MRI were randomized to receive either IFN-b-1b (250 mg) subcutaneously every other day or placebo for 2 years, or until conversion to CDMS. Compared with the placebo group, the interferon group demonstrated a significant delay in time to diagnosis of CDMS with the probability of conversion over 2 years being 69% in the interferon-treatment arm compared with 85% in the placebo group (P < 0.001). While there is currently no available data regarding glatiramer acetate's effect on CIS, a randomized, placebo-controlled trial is currently in progress [11] .
Arguments against early initiation of DMT have generally focused on the inability to predict disease course and the existence of a 'benign' form of MS, which potentially may not require unnecessary commitment to the adverse effects of DMTs. Importantly, a recent longitudinal study of patients believed to have a 'benign' form of MS at 10 years, as identified by Expanded Disability Status Scale (EDSS) scores of three or less, revealed that two decades later, 21% had progressed to require the use of a cane for ambulatory assistance [12] . As such, not treating this population on the basis of their 'benign' label may have negative consequences. Moreover, this study highlights the need for better criteria to identify which patients will remain with mild disability and which of them will progress.
Comparative studies of existing therapies
Until recently, no blinded randomized, controlled trials of 2 years or longer had compared any of the six DMTs. Three recent studies, the Rebif versus Glatiramer Acetate in Relapsing MS Disease (REGARD), Betaseron versus Copaxone in MS with Triple-Dose Gadolinium and 3-T MRI Endpoints (BECOME) and Betaseron Efficacy Yielding Outcomes of a New Dose (BEYOND trials), have provided data on comparative efficacy, specifically head-to-head comparisons of interferons with glatiramer acetate.
The REGARD trial was a 96-week study of 764 patients with relapsing forms of MS randomized to receive either IFN-b-1a 44 mg injections three times weekly versus glatiramer acetate [13] . The primary outcome measure was time to first relapse, and results demonstrated no difference between groups. Additionally, 460 of the 764 patients underwent MRI every 6 months for secondary and tertiary outcome measures. No difference in the number of new or enlarging T2 lesions per patient per scan was noted between the glatiramer acetate-treated group (0.7 lesions) compared with the interferon-treated group (0.6 lesions). There was, however, a statistically significant reduction of 50% in the number of gadolinium-enhancing lesions per patient per scan favoring the interferon-treated group, along with a significant reduction in combined unique lesions (gadolinium-enhancing lesions and new nonenhancing T2 lesions) in favor of patients treated with interferon. Such a difference appears consistent with interferon's reduction of BBB permeability. With respect to the tertiary outcome measure, annualized relapse rate, no difference was identified between groups, with 0.30 relapses per patient per year in the interferon-treated group and 0.29 relapses per patient per year in the glatiramer acetatetreated group. There were no unexpected adverse events in REGARD. In concert with their respective side effect profiles, the interferon-treated group demonstrated more flu-like symptoms, headaches and liver enzyme abnormalities, and the glatiramer acetate-treated group experienced more injection-site reactions and postinjection reactions.
Of interest, the annualized relapse rate in this study, as well as has been observed in several recent trials [14] , was significantly lower in comparison to the pivotal trials for both IFN-b and glatiramer acetate. Investigators commented that there were 45% fewer relapses during the course of the study than anticipated. Specifically, in REGARD, patients experienced only two relapses in 2 years compared with an average of three relapses in 2 years in the IFN-b-1a and glatiramer acetate pivotal trials. The low event rate in REGARD may have rendered it statistically underpowered to detect differences between the treatment groups. Moreover, it is unclear what the significance of this low relapse rate and that observed in other trials is, specifically whether or not it reflects a changing disease population, likely influenced by early diagnosis and treatment. Lower event rates will likely have implications for future trials, requiring larger populations to detect significant differences between treatments, which will likely impose temporal and economic constraints on MS research studies.
Another trial which involved a head-to-head comparison between interferon and glatiramer acetate was BECOME, the first investigator initiated, single-site, randomized, prospective, rater-blinded trial directly comparing these agents. BECOME was a 24-month study of 75 patients with relapsing MS or CIS randomized to IFN-b-1b or glatiramer acetate [15] . Patients underwent monthly triple-dose gadolinium-enhanced 3-tesla MRI for 24 months. Whereas the REGARD trial identified a significant difference in MRI outcome measures in favor of the interferontreated group, in BECOME, surprisingly, there was no difference in the primary outcome measure of average number of combined active lesions (gadolinium-enhancing lesions plus new nonenhancing T2 lesions) per patient per scan between treatments. Whether or not this relates to the difference in MRI technique used in this study compared with the standard 1.5-T MRI with single dose gadolinium remains unclear, but it certainly raises issues about the sensitivity of conventional imaging to characterize radiographic disease activity. Additionally, there were no differences between the two groups in any of the secondary clinical outcomes: annualized relapse rate and disability progression as determined by the EDSS and Multiple Sclerosis Functional Composite Scale (MSFC) [16] . Of note, however, the study was not powered to detect significant clinical changes.
The BEYOND study was designed to investigate the efficacy, tolerability and safety of double-dose (500 mg) IFN-b-1b versus the standard 250 mg dose versus a comparative glatiramer acetate-treatment arm. The primary outcome measure, time to first relapse, was similar in all three treatment arms with no statistically significant superiority of the 500 mg IFN-b-1b dose over the 250 mg dose nor glatiramer acetate [17] . Again, in contrast to previous trials, a very low relapse rate was noted in this study population.
Although these head-to-head data are extremely helpful in rationalizing the use of all agents as treatments, individual response to a particular agent remains unknown, and the choice of therapy generally rests on a thorough review of the dose regimens and side effect profiles specific to each agent. Tolerance of side effects can play a critical role in determining compliance with injectable therapies and should therefore be discussed at length prior to initiation of treatment.
Combination therapies and alternative dosing regimens
Combinations of conventional either DMTs or additions of immunosuppressive agents to DMT or both may provide synergistic effects to treatment regimens that could potentially benefit patients with MS. Agents that should be considered for combination therapy are those with unique mechanisms of action with the potential to provide cumulative or synergistic efficacy. In light of the mechanistic differences between the DMTs, combination therapy using interferon and glatiramer acetate may enhance the effects on each agent used alone. A 6-month pilot trial of 32 patients with RRMS assessed the safety of IFN-b-1a and glatiramer acetate and compared the number of gadolinium-enhancing lesions in patients receiving combination versus either treatment alone [18, 19] . No adverse events or any increases in gadolinium-enhancing lesions were noted. Currently, a 3-year National Institutes of Health (NIH) funded, randomized, blinded trial, Combi-Rx, is underway comparing relapse rate reduction between three treatment arms: IFN-b-1a 30 mg intramuscular weekly; glatiramer acetate 20 mg subcutaneously daily; versus a combination of interferon and glatiramer acetate. Results are expected in 2011.
In addition to combinations of DMTs, combination induction strategies using immunosuppresants and DMTs are also of interest as a means to enhance currently available therapies. An example of this is mitoxantrone (MTX) induction therapy prior to inititation of DMT. MTX, an FDA approved treatment for relapsing forms of secondary prgressive MS (SPMS) and worsening RRMS, is an anthracenedione DNA intercalator, whose immunomodulatory mechanisms include an antiproliferative effect on T cells as well as suppression of humoral immunity. The rationale supporting this approach involves an initial priming of the immune system to enhance the action of the maintenance DMT.
An open label study evaluating sequential maintenance treatment with glatiramer acetate after MTX in a consecutive series of 27 patients with very active RRMS reported a sustained 90% reduction in annualized relapse rate (P < 0.001) with stabilization or improvement in disability at a mean of 36 months from start [20] . The induction protocol was varied involving initially 20 mg monthly MTX infusions for 6 months, later shortened to 3 months, accompanied by 1 g intravenous methylprednisolone (IVMP) with subsequent 10 mg pulse doses every 3 months until a 6 month period of clinically stability, at which time glatiramer acetate treatment was initiated. MRIs obtained for the first 10 patients demonstrated no gadolinium activity after 2 years treatment. Only two patients experienced relapses after withdrawal of MTX. A single case of secondary acute myeloid leukemia (AML) was identified. While this is promising, clearly there are several limitations to this study, specifically the nonrandomized, uncontrolled design as well as the nonstandardized dose protocol.
In a randomized trial of 40 patients investigating MTX induction for 3 months followed by glatiramer acetate treatment compared with glatiramer acetate alone, a statistically significant reduction, of approximately 90%, in mean total number of gadolinium-enhancing lesions at 15 months was identified in the induction group [21] . There was also a trend towards fewer relapses with induction. At 2 years, follow-up of 28 patients revealed a reduction in MRI activity by 90% in the induction group compared with 59% in the glatiramer acetate group; however, there were similar mean relapse rates for both groups.
Prior studies using MTX induction with maintenance IFN-b have been somewhat disappointing with recurrent relapse activity occurring months after withdrawal of MTX and return to interferon in some patients [22] . Results of a 3-year study by Edan and colleagues [23] evaluating MTX induction therapy followed by IFNb-1b versus IFN-b-1b alone in 109 active MS patients were more encouraging. Here, the induction regimen involved 1 g of IVMP and 20 mg of MTX infused monthly for 6 months thereafter followed by initiation of IFN-b-1b. The annualized-relapse rate with induction was significantly lower, 0.44 compared with 1.14 in the IFN-b only group, demonstrating a 56% benefit. Additionally, 26% of the IFN-b only group demonstrated evidence of worsening disability as measured by an increase of greater than one point on EDSS, compared with only 9% of induction-treated patients.
Although these data are encouraging, it is important to take into account the myriad of side effects and risks associated with MTX therapy before entertaining this strategy. These include: leukopenia, infections, amenorrhea, alopecia and nausea as well as known severe risks, including cardiotoxicity with decrease in ejection fraction, myelosuppresion and secondary AML. Although the exact risk of secondary AML remains uncertain, a recent study by Pascual and colleagues [24] revisited this issue and found the incidence to be 2.83% (95% confidence interval 1.2-4.4), substantially higher than previously estimated as 0.07% in a review of 1378 MTX treated patients [25] . In light of MTX's risk-to-benefit ratio, induction strategies may offer the possibility of achieving short-term benefits without incurring the long-term risks such as cumulative cardiotoxicity and leukemia.
In summary, while DMT cocktails pose an attractive therapeutic target, the potential risk of unexpected adverse events, not evident with monotherapy, should be emphasized. An obvious example of this was the appearance of progressive multifocal leukoencephalopathy (PML) in patients receiving the natalizumab and IFN-b-1a combination, as discussed in a later section.
In addition to combination therapies, information regarding alterations in dose regimens is also a focus of interest. In the BEYOND trial, double dose (500 mg) IFN-b-1b every other day did not confer any additional efficacy when compared with the conventional dose. Double dose glatiramer acetate was also compared with standard dosing in a recent 9-month, double-blind parallel group study assessing the efficacy and safety of 40 mg subcutaneously daily, compared with 20 mg daily in patients with RRMS. The primary endpoint, cumulative gadolinium-enhancing lesions at months 7, 8, and 9, demonstrated a trend favoring high-dose glatiramer acetate with a 38% relative reduction evident at 3 months (P ¼ 0.0898). Also, time to first relapse was significantly delayed in the high-dose group (213 days versus 80 days; P ¼ 0.0367). These results suggest a potential role for a starting dose of 40 mg of glatiramer acetate followed by maintenance 20 mg glatiramer acetate after 3 months. High-dose glatiramer acetate was well tolerated in this study, demonstrating a similar safety profile to low dose [26] . A phase III trial is currently in progress to further validate these results.
Oral therapies
Several new oral therapies are currently under investigation. Should long-term studies demonstrate similar or better efficacy and safety compared with current DMTs, novel oral therapies will expectedly pose attractive firstline agents for MS patients reluctant to comply with injectable treatments. Improvement in long-term adherence offers the important potential to optimize therapeutic outcomes.
Fingolimod FTY720, or fingolimod, is a promising new oral immunomodulatory agent under investigation for relapsing MS. It is a synthetic analog of sphingosine 1 phosphate (S1P), which modulates S1P receptors on thymocytes and lymphocytes to sequester lymphocytes in secondary lymphoid organs, inhibiting their egress to the CNS. In a recent phase II trial lead by Kappos, et al. [27] , fingolimod given once daily demonstrated a significant and rapid reduction in MRI measures of inflammation and in relapse-related clinical end points in MS patients. In this double-blind, randomized placebo-controlled study, 281 patients with relapsing MS were randomized to receive fingolimod (1.25 mg or 5 mg orally/daily) or placebo with a primary end-point measure of total gadolinium-enhancing lesions on MRI at monthly intervals for 6 months. The mean total number of gadolinium-enhancing lesions was lower in both treatment groups (1.25 mg: one lesion, P < 0.001; 5 mg: three lesions, P < 0.006) compared with placebo (5 lesions). In addition, the annualized relapse rate was 0.77 in the placebo group compared with 0.35 in the 1.25 mg fingolimod group (P ¼ 0.009) and 0.036 for the 5 mg fingolimod group (P ¼ 0.01). In the extension phase, both the number of gadolinium-enhancing lesions as well as relapse rates remained low in both fingolimodtreatment groups, and both measures decreased in patients switched from placebo to fingolimod.
Adverse events associated with fingolimod included nasopharyngitis, dyspnea, headache, diarrhea and nausea. A case of posterior reversible leukoencephalopathy syndrome (PRES) occurred in the 5 mg treatment group. In addition, lymphopenia, clinically asymptomatic elevations in liver alanine aminotransferase, bradycardia and pulmonary function test abnormalities were also reported. Whereas the results of this study are encouraging, two larger phase III trials are currently underway, including one comparing fingolimod to an approved DMT. Of interest, in-vitro cell culture studies have shown FTY720 to increase both mature and immature oligodendrocyte populations, suggesting a unique potential impact on remyelination [28, 29] .
Fumaric acid
Fumaric acid is an immunomodulator used for the treatment of psoriasis. Novel fumaric acid esters with better tolerability have recently been developed. An oral fumaric acid derivation, BG00012, is currently being studied in two-phase III trials in patients with RRMS [30] . In-vitro studies demonstrate that fumaric acid inhibits expression of proinflammatory adhesion molecules and cytokines as well as exhibiting neuroprotective effects [31, 32] . A 24-week phase II double-blind placebo-controlled trial comparing BG00012 (120, 360 or 720 mg) daily to placebo demonstrated a significant reduction of gadoliniumenhancing lesions in the highest dose BG00012-treatment group [33] . Moreover, the BG00012-group demonstrated 48% fewer T2 lesions and 53% fewer T1-black holes compared with placebo (P ¼ 0.001). The most common side effects included headache, nasopharyngi-tis, nausea and flushing, with no significant difference between the treatment and placebo arms. A large phase III study on fumaric acid in RRMS is now recruiting.
Cladribine
Cladribine is an adenosine deaminase-resistant purine nucleoside analog that preferentially depletes subpopulations of lymphocytes. Currently, its indications are oncologic, as an effective treatment for hairy cell leukemia and lymphoma. Preliminary studies of parenteral cladribine in MS demonstrated efficacy in clinical and MRI parameters with a safety profile of doses up to 2.1 mg/kg similar to placebo. Doses of 0.7 to 2.1 mg/kg can be achieved with oral preparations, and two studies examining the safety and efficacy of oral cladribine are underway. A 2-year phase III randomized, placebo-controlled trial of cladribine monotherapy in patients with RRMS and EDSS scores of 0-5.5 has completed enrollment. The primary outcome measure is relapse rate from baseline to week 96. Another phase II study combining IFN-b-1a 44 mg thrice weekly with oral cladribine is underway with a primary outcome measure of number of new gadolinium-enhancing lesions from baseline to week 96 [34] .
Teriflunomide
Teriflunomide is a dihydro-orotate dehydrogenase inhibitor, which has demonstrated immunomodulatory effects including the ability to suppress experimental allergic encephalomyelitis. A recent phase II study assessing safety and efficacy of oral teriflunomide in relapsing forms of MS found the agent to be well tolerated and effective in reducing MRI lesions [35] . In this 36 week randomized, double-blind, placebo-controlled trial in relapsing forms of MS, 179 patients were randomized to either placebo, teriflunomide 7 mg/day or teriflunomide 14 mg/day. MRI brain scans were obtained every 6 weeks with a primary endpoint of combined unique active lesions per scan. Secondary endpoints included MRI disease burden, relapse frequency, and disability accumulation. The median number of combined unique active lesions per scan was significantly lower in the treatment groups: 0.5, 0.2 and 0.3 in the placebo, teriflunomide 7 mg/day (P < 0.03 vs. placebo), and teriflunomide 14 mg/day (P < 0.01 vs. placebo) groups respectively. Moreover, teriflunomide-treated patients also had significantly fewer T1 enhancing lesions per scan, new or enlarging T2 lesions per scan, and new T2 lesions, with the higher-dose group demonstrating a significant reduction in T2 disease burden. Additionally, the higher-dose treatment group exhibited a trend towards lower annualized relapse rates, as well as significantly fewer patients demonstrating an increase in disability. Treatment was well tolerated with similar numbers of adverse events in all treatment groups. Two phase III studies investigating the efficacy and safety of teriflunomide in patients with CIS and RRMS are currently recruiting.
HMG-CoA reductase inhibitors, statins
Interest in hydroxy-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors, or statins, as potential therapeutic agents in MS is based on several experimental studies demonstrating a possible anti-inflammatory, potentially neuroprotective effect on the disease [36, 37] . Studies in experimental autoimmune encephalitis and in-vitro observations in immunocompetent cells suggest that statins may exert immunomodulatory effects on both T cells and monocytes [38, 39] . A small open label study involving 30 RRMS patients taking oral simvastatin demonstrated a decrease in the number and volume of gadolinium-enhancing lesions by 44 and 41%, respectively [40] . This was the first study to suggest a potential role for statins in the treatment of RRMS as determined by MRI measures.
Studies to evaluate the safety and efficacy of statins are currently in progress, but effects of add-on statin therapy with interferons have raised concerns of a potentially incompatible, antagonistic effect of the combination. In-vitro studies suggest that statins may block interferon-signaling pathways, thereby decreasing therapeutic efficacy [41] . In a double-blind, placebo-controlled trial of 24 patients randomized to receive atorvastatin (40 mg or 80 mg) in combination with subcutaneous IFN-b-1a versus placebo, there was either an increase in relapses or MRI-enhancing lesions or both in 10 of the 15 patients receiving combination treatment versus only one of nine in the placebo group [42] . In contrast, however, another trial using only 20 mg of atorvastatin did not identify any differences with combination therapy [43] . Furthermore, interim analysis of the SIMCOMBIN trial investigating 80 mg of simvastatin or placebo plus IFN-b-1a 30 mg intramuscularly weekly also found no antagonistic effects of the interferon-statin combination [44] . A prior pilot study of 12 CIS patients randomized to placebo or simvastatin 80 mg daily plus IFN-b-1a intramuscularly weekly found the combination to be safe and well tolerated [45] . The safety and efficacy of statin monotherapy in CIS is currently being investigated with results expected next year.
Symptomatic therapy -4-aminopyridine/Fampridine
A very promising oral symptomatic therapy is Fampridine-SR, the sustained release formulation of 4-aminopyridine (4-A,P). Fampridine is unique among novel treatments as a means to optimize functional reserve by enhancing conduction of damaged demyelinated axons via potassium channel blockade. In a phase-III randomized, double-blind, placebo-controlled trial of Fampridine, administered as adjuctive therapy, there was a significant improvement of 25% in walking speed seen after 14 weeks in 34.8% of the Fampridine group compared with 8.3% receiving placebo [46] . Walking speed was assessed by timed 25-foot walk. Fampridine has a narrow efficacy-to-toxicity window with respect to risk of treatment-associated seizures. In this study, discontinuations due to adverse events occurred in 4.8% of the 229 treated patients, and none of the 72 patients in the placebo group. Three were considered serious: specifically, influenza, sepsis and anxiety. A focal seizure, observed during sepsis, was considered possibly related to treatment. An additional 13 patients in the treatment group experienced various serious adverse events, none of which, however, were considered related to or led to discontinuation of treatment.
Monoclonal antibodies
Monoclonal antibodies (mAbs) are a group of selective agents which bind to specific molecules on the surface of targeted cells, for example T cells or B cells, both of which appear integral in the pathogenesis of MS. A number of mAbs currently approved or in clinical trials are considered among the most promising new therapies for MS. These include natalizumab, alemtuzumab, rituximab and daclizumab. While several of these agents have shown considerable promise as targeted immunotherapies, there are several limitations they pose including associated severe adverse events, infusion-related reactions, and development of neutralizing antibodies [47] .
Natalizumab
Natalizumab is a humanized mAb that targets a-4 integrin, an adhesion molecule on the surface of leukocytes, thereby interfering with entry of activated T cells into the CNS compartment. Reapproved in June 2006 by the US FDA and European authorities as monotherapy for the treatment of active relapsing forms of MS, natalizumab is reserved for patients that have failed to respond adequately to or cannot tolerate other conventional DMTs. To review, based on positive interim analyses of two phase III trials, AFFIRM [48] and SENTINEL [49] , the FDA initially approved natalizumab in November 2004. Unfortunately, despite impressive efficacy results, natalizumab was unexpectedly quickly withdrawn from the market in February 2005, nearly 4 months after approval, after two patients receiving natalizumab in combination with IFN-b-1a developed PML, an infection secondary to the reactivation of a commonly latent virus, the John Cunningham virus [50] . Additionally, a patient with Crohn's disease treated with natalizumab, along with other immunosuppressants, also developed PML [51] . As such, an exhaustive investigation of all patients treated with natalizumab was conducted and no additional cases of PML had been identified over a period of 18 months, leading to the drug's conditional reapproval. Moreover, a risk management plan to tighten PML surveillance was implemented, referred to as the TOUCH (Tysabri Outreach Unified Commitment to Health) program [52] .
Although it remains uncertain whether John Cunningham virus reactivation resulted from a broad immunosuppression secondary to combination therapy with interferon or as a specific effect of the mAb itself, natalizumab, nevertheless, serves as the prototypical lesson of the perils involved when novel high-efficacy therapies with uncertain long-term safety profiles are introduced into a treatment paradigm. To date, there are over 17 000 or more patients on natalizumab worldwide with no new cases of PML reported. As this is extremely encouraging, it is important to emphasize that the time period of this safety data is still less than 2 years, the time period after which PML cases were identified. As such, it is still admittedly premature to determine the exact risk of developing PML. Informed discussions between clinicians and patients regarding natalizumab's as yet undefined risk-to-benefit ratio need to be emphasized when considering use of this agent in those failing conventional DMT.
Alemtuzumab
Alemtuzumab (CAMPATH-1H) is a humanized mAb that binds to the CD52 antigen on the surface of thymocytes, natural killer cells and B cells. It is FDA approved for the treatment of fludarabine-resistant chronic lymphocytic leukemia. Binding to the CD52 antigen results in antibody-dependent lysis and rapid removal of T cells from blood, bone marrow and organs. This T-cell depletion lasts for an extended period of time, up to 16 months. A study by Coles and colleagues [53] assessed the use of alemtuzumab in early very active MS and demonstrated a significant reduction in relapse rate of 91% as well as improvement in EDSS at 1 year. On the basis of these results, investigators designed the CAMMS223 trial. In this study, patients with RRMS were randomized to receive alemtuzumab or 44 mg IFN-b-1a subcutaneously three times a week. The trial was interrupted in 2005 due to three unexpected cases of idiopathic thrombocytopenia purpura (ITP), including two fatalities. In addition to ITP, autoimmune thyroiditis has also been identified in MS patients treated with alemtuzumab. After the suspension of alemtuzumab, three additional cases of ITP were identified early and treated successfully. A 2-year interim analysis presented at the 2007 AAN Annual Meeting demonstrated that the alemtuzumab-treatment group had a 75% or greater reduction in risk of relapse (P ¼ 0.00328), and a 65% reduction in risk for 6-month sustained accumulation of disability, as compared with interferon [54] . Three-year results were presented at ECTRIMS in October 2007 [55] . Analysis of the primary end point demonstrated the alemtuzumab-treated group experienced a 73% relapse reduction after 3 years when compared with patients taking interferon. Time to sustained accumulation of disability, another primary endpoint, showed that patients taking alemtuzumab experienced at least a 70% reduction in risk for progression to clinically significant disability compared with those taking interferon. Further results are expected at the 2008 AAN Meeting.
Despite its efficacy, potentially serious adverse effects can occur months or years after dosing, specifically a 20% risk of autoimmune thyroiditis and a 2% risk of ITP [56, 57] . With careful monitoring for both disorders in place, the study suggests early diagnosis can lead to successful treatment. Two phase III trials comparing alemtuzumab to IFN-b-1a are currently recruiting, one in DMT naïve patients and another in patients having failed an adequate trial of DMT.
Rituximab and B cell involvement
There is a growing body of evidence supporting the role of b lymphocytes in the immunopathogenesis of MS. While the exact mechanism remains unknown, several plausible possibilities include contribution to antibodymediated inflammation-based myelin damage, encouragement of T-cell mediated tissue destruction, and a role in neurodegeneration [58] . As such, an agent targeting B cells offers a logical approach to MS therapy. Rituxmab is a chimeric murine/human mAb that targets and selectively depletes CD20, an antigen present on pre-B and mature b lymphocytes, however not found on hematopoietic stem cells, plasma cells or in normal tissues. The exact function of CD20 is not known. Rituxmab is currently FDA approved for the treatment of non-Hogdkin's lymphoma, refractory rheumatoid arthritis and diffuse B-cell lymphoma.
Results of a phase II randomized, placebo-controlled trial of 104 patients with RRMS receiving either rituximab 1000 mg i.v. 2 weeks apart versus placebo demonstrated a significant reduction of 91% in mean total gadoliniumenhancing lesions in the treatment group compared with placebo (P < 0.0001) [59] . This reduction was achieved by week 12 and sustained for the duration of the study. The number of new gadolinium-enhancing lesions and T2 lesion volume were also reduced. Moreover, there was a trend towards lower annualized relapse rates that reached significance by week 24, but did not carry through to week 48. Rituximab was well tolerated with similar mild to moderate adverse effects reported in both groups, albeit a higher incidence of infusion reactions in the treatment group.
The presence of B-cell follicle-like structures in the cerebral meninges of two out of three patients with secondary progressive MS suggests humoral autoimmunity may factor distinctly in progressive disease forms [60] . A preliminary study of rituxmab in patients with primary progressive MS (PPMS) identified a limited effect on B cells in the cerebrospinal fluid [61] . A separate phase II trial in PPMS is currently completed and results should be available this year. Rituximab also appears to be a promising treatment option for patients with neuromyelitis optica (NMO), a humorally mediated demyelinating disease with preference for the spinal cord and optic nerves. In an open label study by Cree and colleagues [62] , there was a decrease in relapse rates and improvement in disability scores in patients with NMO that had failed prior treatment with other immunosuppressant regimens.
In 2007, the FDA reported that two cases out of 10 000 patients with systemic lupus erythematosus (SLE) who had received rituximab had developed PML [63] . Of note, these patients had also been treated previously with other immunosuppressants and PML, itself, has been reported in the SLE population in patients that have not been treated with rituximab. As such, a causal relationship between PML and rituximab treatment cannot be established from this report. Nevertheless, clinicians and patients should be aware of this risk when considering rituximab as a treatment option, particularly in those patients with a prior history of immunosuppressant therapy.
Daclizumab
Daclizumab, an FDA approved treatment for the prevention of graft versus host disease in renal transplant patients, is a humanized mAb that binds to CD25, the a-chain of interleukin (IL)-2 receptor, resulting in decreased IL-2-mediated stimulation of T-cell function. Preliminary studies have evaluated the effect of adding daclizumab to IFN-b therapy. In an open-label trial of 10 patients with MS demonstrating high clinical and MRI activity, there was a 78% reduction in new gadolinium-enhancing lesions [64] . Montalban and colleagues presented results of a recent phase II study of daclizumab add-on therapy at the 2007 ECTRIMS meeting. In this study, the CHOICE trial, 230 actively relapsing MS patients on IFN-b were randomized to either daclizumab (1 mg/kg or 2 mg/kg subcutaneously) every 2 weeks for 24 weeks or placebo. There was a significant reduction of 72% in mean number of new or enlarging gadolinium-enhancing lesions at weeks 8-24 in the 2 mg/kg treatment arm compared with placebo (P ¼ 0.004). In addition, a 25% reduction in gadolinium-enhancing lesions was seen on the lower dose, albeit not statistically significant. Moreover, a nonsignificant reduction of 33% in relapse rate was noted in the high dose group; however, the study was not designed to compare relapse rates. Adverse effects included infections, urinary tract infections and cutaneous events. Serious infections were more common in the high-dose treatment group [65] .
Antigen based immune therapy -MBP8298/ DNA vaccination -BHT-3009
Antigen-based immune therapy is an attractive therapeutic approach to the treatment of autoimmune disorders. Tolerance can be induced to specific antigens by oral application of, for example, myelin basic protein (MBP) resulting in production of antigen specific regulatory T cells in the periphery. This triggers development of bystander suppression after antigen recognition by the target organ. Several studies, both experimental and clinical, have been conducted in an attempt to implement antigen-specific therapy, albeit with limited clinical success in humans. For instance, trials of oral myelin [66] and altered peptide ligands derived from immunodominant peptides of MBP were disappointing [67] . An approach which has shown some promise, of late, involves the repetitive application of MBP8298, an MBP derived peptide with residues representing the minimal epitope necessary for antibody response in the CSF of MS patients. On the basis of data from an open-label study investigating MBP8298 in chronic, progressive forms of MS, 500 mg of MBP8298 induced lasting immunological tolerance, interestingly in a subclass of patients positive for specific HLA-DR haplotypes DR2, DR4 and DR7 [68] . A phase II trial in chronic progressive disease demonstrated that fewer patients in the treatment group progressed, as determined by EDSS scores, compared with placebo, the effect most impressive in either the subgroup HLA-DR2 or DR4 individuals or both [69] . A 2-year phase II/III study investigating MBP8298 in SPMS patients with specific HLA-DR2/4 haplotypes is currently recruiting.
DNA-derived immunization could also potentially augment the efficacy of antigen-induced tolerance. An example is BHT-3009, a DNA plasmid vaccine that encodes full-length MBP. In a phase II trial led by Garren and colleagues [70] , 289 patients were randomized to placebo, 0.5 mg BHT-3009 IM or 1.5 mg BHT-3009. Median rate of development of gadolinium-enhancing lesions between 24 and 28 weeks was decreased by 50% in the 0.5 mg group, with no significant difference, however, noted in the 1.5 mg group. Additionally, no significant effect was noted on relapse rate or T2 lesion burden.
Remyelination/repair and neuroprotection
The last decade has marked several advances in the understanding of mechanisms responsible for oligodendrogenesis and myelination with several plausible translational targets identified. Whereas the clinical application of such strategies is likely decades away, unraveling the complexities of remyelination is critical to our understanding of repair of tissue damage and recovery of function. In addition to laboratory efforts to demystify remyelination, a focus on neuroprotective agents is an area of great interest in an effort to identify methods to maintain axonal integrity and promote regeneration.
Individualizing therapies
As the therapeutic horizon continues to change with the advent of new options, choice of first line therapy will undoubtedly become a more complicated decision. Natalizumab has certainly taught us the caveat of short-term safety data and unexpected adverse events in exchange for potentially better outcomes. Without question, the wide spectrum and unpredictable nature of MS itself limits our ability to prognosticate well, and clinicians continue to face a trial and error treatment period, which potentially impedes a time of critical therapeutic importance in the course of our patients' disease. Several new modalities, which aim to identify treatment response, are currently being investigated. A stratification of therapeutic subgroups could foster the development and application of individualized therapies. Knowing which therapy will work best early on would be paramount. One area of great promise involves the field of proteomics. Proteomics is the study of patterns of serum proteins from individual patients. Such fingerprint profiles could be instrumental in discovery of biomarkers that indicate not only a particular disease type, but also response to specific therapies.
Conclusion
In summary, a plethora of novel agents in various clinical trials are currently being tested with hopes to broaden the currently limited therapeutic arsenal. These include agents focusing on optimizing disease modification as well as neuroprotective and repair strategies. While several current and future investigational therapies appear promising, it is clear that a greater understanding of disease pathophysiology is still needed. As neuropathological studies have demonstrated, patterns of disease are as variable, if not more heterogeneous, than clinical subtypes [71] . It remains to be seen if therapies under clinical investigation will replace the available armamentarium of DMTs or find designation among a bevy of individualized therapies specific to either disease subtype or treatment response or both.
